Hims & Hers shares surge 50% after Novo Nordisk drops patent infringement case over compounded weight loss drugs

Hims & Hers experienced a significant surge in shares, increasing by 50%, following the news that Novo Nordisk dropped its patent infringement case against the telehealth company. The agreement allows Hims to sell Novo's branded medicines, which could enhance Hims' product offerings and market position. Investors reacted positively to this development, reflecting confidence in Hims' growth potential. This collaboration may open new revenue streams for Hims through medication sales. The case drop has removed a potential legal threat, contributing to the bullish sentiment around the stock.